Quantcast
Home > Quotes > INSP

Inspire Medical Systems, Inc. Common Stock (INSP) Quote & Summary Data

INSP 
$64.02
*  
1.49
2.27%
Get INSP Alerts
*Delayed - data as of Aug. 23, 2019  -  Find a broker to begin trading INSP now
Exchange:NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
70
Today's High / Low
$ 66.28 / $ 63.2995
Share Volume
209,299
90 Day Avg. Daily Volume
294,658
Previous Close
$ 65.51
52 Week High / Low
$ 69.7076 / $ 35.43
Market Cap
1,530,710,133
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.11
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.01

Intraday Chart

Shares Traded

Share Volume:
209,299
90 Day Avg. Daily Volume:
294,658

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.11

Trading Range

The current last sale of $64.02 is 80.69% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 66.28 $ 69.7076
 Low: $ 63.2995 $ 35.43

Company Description (as filed with the SEC)

We are a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Our proprietary Inspire system is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. We have developed a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. A significant body of clinical data, which includes a publication in the New England Journal of Medicine and more than 75 peer-reviewed publications, supports the safety and efficacy of Inspire therapy. Inspire therapy received premarket approval ("PMA") from the U.S. Food and Drug Administration ("FDA") in April 2014 and has been commercially available in certain European markets since November 2011.  ... More ...  



Risk Grade

Where does INSP fit in the risk graph?


Risk Grade Scale



Consensus Recommendation

Analyst Info